NCT02097706View on ClinicalTrials.gov

A Novel Drug for Borderline Personality Disorder

PHASE2RecruitingINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

January 31, 2015

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Borderline Personality Disorder
Interventions
DRUG

NMDA receptor antagonist (active drug)

OTHER

Lactose packed capsule (inert/inactive arm)

Trial Locations (1)

3004

RECRUITING

Monash Alfred Psychiatry Research Centre, Melbourne

All Listed Sponsors
lead

The Alfred

OTHER